Filing Details

Accession Number:
0001104659-22-120780
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-11-21 16:31:14
Reporting Period:
2022-11-17
Accepted Time:
2022-11-21 16:31:14
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1781174 Acrivon Therapeutics Inc. ACRV () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1315082 Ra Capital Healthcare Fund Lp 200 Berkeley Street, 18Th Floor
Boston MA 02116
Yes No Yes No
1346824 Ra Capital Management, L.p. 200 Berkeley Street, 18Th Floor
Boston MA 02116
Yes No Yes No
1384859 Peter Kolchinsky C/O Ra Capital Management, L.p.
200 Berkeley Street, 18Th Floor
Boston MA 02116
Yes No Yes No
1619841 M. Rajeev Shah C/O Ra Capital Management, L.p.
200 Berkeley Street, 18Th Floor
Boston MA 02116
Yes No Yes No
1825376 Ra Capital Nexus Fund Ii, L.p. 200 Berkeley Street, 18Th Floor
Boston MA 02116
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-11-17 994,706 $0.00 994,706 No 4 C Indirect See Footnotes
Common Stock Acquisiton 2022-11-17 3,389,500 $12.50 4,384,206 No 4 P Indirect See Footnotes
Common Stock Acquisiton 2022-11-17 426,302 $0.00 426,302 No 4 C Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See Footnotes
No 4 P Indirect See Footnotes
No 4 C Indirect See Footnotes
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series B Preferred Stock Disposition 2022-11-17 2,452,947 $0.00 994,706 $0.00
Common Stock Series B Preferred Stock Disposition 2022-11-17 1,051,263 $0.00 426,302 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. On November 17, 2022 each share of Series B Preferred Stock (the "Preferred Stock") converted into Common Stock of the Issuer at a ratio of 1-for-2.466 upon closing of the initial public offering of the Issuer's common stock without payment of further consideration. The shares had no expiration date.
  2. These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund").
  3. These securities are held directly by RA Capital Nexus Fund II, L.P. (the "Nexus Fund II").
  4. RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund II. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.